NASDAQ$LGVN
Longeveron Inc-A · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Longeveron Inc-A reported a net loss of $5.0 million for Q2 2025 amid increased R&D spending on BLA-enabling activities.
The company posted total revenues of $316,000 for the quarter, down from $468,000 a year earlier, primarily due to lower contract manufacturing demand. Operating expenses rose sharply to $5.5 million driven by higher personnel and clinical development costs. Cash and cash equivalents stood at $10.3 million at quarter end, with management projecting runway into Q1 2026 after recent financing.
- Q2 revenues declined 32% year-over-year to $316,000 as contract manufacturing activity slowed.
- Net loss widened to $5.0 million from $3.4 million in Q2 2024 due to elevated R&D and G&A expenses.
- R&D expenses increased 72% to $3.0 million, reflecting BLA-enabling CMC and manufacturing readiness investments.
- ELPIS II HLHS trial reached full enrollment; top-line data expected in Q3 2026 with potential BLA filing late 2026.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$316K
Revenue by segment
Longeveron · $316K total across 3 segments · Q2 2025
- Clinical trial revenue$298K—94.3%
- Contract manufacturing revenue$12K—3.8%
- Contract manufacturing lease revenue$6K—1.9%
Forward guidance
Management expects existing cash plus recent financing to fund operations into Q1 2026; anticipates potential BLA filing for HLHS in late 2026 if ELPIS II succeeds.
Tailwinds
- ELPIS II fully enrolled with top-line data expected Q3 2026
- RMAT and Fast Track designations received for Alzheimer's program
- XPRIZE Milestone 1 Award received
Headwinds
- Substantial doubt about going concern without additional financing
- Operating expenses expected to rise through 2026 for CMC readiness
- Need to secure further capital or partnerships for Alzheimer's program
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+22.2%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +0.7% | -11.0% | +4.3% | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro